Teresa Regan
Human Resources Officer at NEON THERAPEUTICS, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Richard Gaynor | M | 74 | 8 years | |
| Frederick B. Oleson | M | - | 27 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Perez | M | 59 | 12 years | |
| David McGirr | M | 69 | 12 years | |
| Ken Bate | M | 73 | 13 years | |
| Hugh O'Dowd | M | 59 | 4 years | |
| Eric S. Lander | M | 67 | 7 years | |
| Robert Tepper | M | 68 | 7 years | |
| Mary Crosby Stack | F | - | - | |
| Cary Pfeffer | M | 61 | 5 years | |
| Edward S. Campanaro | M | - | - | |
| Julian Adams | M | 69 | 1 years | |
| Christopher Guiffre | M | 56 | 7 years | |
| Robert Kamen | M | 79 | 5 years | |
| Stephen Sherwin | M | 75 | 5 years | |
| Meryl Zausner | F | 67 | 3 years | |
| Jolie Siegel | F | 48 | 2 years | |
| Andrea Corcoran | F | 61 |
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 4 years |
| J. Singleton | M | 71 | 11 years | |
| Yasir Al-Wakeel | M | 42 | 3 years | |
| Antonin Rollet de Fougerolles | M | 59 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 1 years |
| Bart Jones | M | - | - | |
| Daniella Beckman | F | 45 | 4 years | |
| Timothy J. Douros | M | - | - | |
| Titus M. F. M. Plattel | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 3 years |
| Donna M. Jarlenski | F | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 2 years |
| Gregory Stea | M | 66 | 13 years | |
| Mary E. Taylor | F | 65 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
| Christopher Rovaldi | M | 50 | 4 years | |
| Barbara Weber | M | 67 | 2 years | |
| Robert Bazemore | M | 56 | 2 years | |
| René Russo | M | 49 | 12 years | |
| Bob Ang | M | 49 | 4 years | |
| Jeffrey D. Alder | M | - | - | |
| Halley Gilbert | F | 54 | 6 years | |
| Walter R. Maupay | M | 84 | 11 years | |
| Robert D. Arbeit | M | 76 | 2 years | |
| Susan B. Bayh | F | 64 | 4 years | |
| David W. Martin | M | 82 | 12 years | |
| Francis P. Tally | M | 83 | 9 years | |
| Thomas A. Shea | M | 64 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 6 years |
| Dennis D. Keith | M | 80 | - | |
| Thomas J. Slater | M | - | - | |
| Barry I. Eisenstein | M | 75 | - | |
| Praveen Tipirneni | M | 55 | 13 years | |
| Oliver Fetzer | M | 60 | 5 years | |
| Elizabeth Czerepak | F | 58 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 4 years |
| John Finn | M | 68 | 5 years | |
| David Wood | M | 66 | 3 years | |
| Robert M. Kirsch | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
| Xiang Liu | M | - | 3 years | |
| Anthony S. Murabito | M | - | - | |
| Maureen H. Powers | F | - | - | |
| Aoife Brennan | M | 48 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 54 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Teresa Regan
- Personal Network
